Eli Lilly (LLY) valuation, revenue & earnings

P/E and P/S history, revenue and growth, ROIC vs. cost of capital, segments, earnings and analyst forecasts

At a glance

Market capitalisation$1.0T

Moat ratingWide moat

ValuationExpensive

Revenue, and where it comes from$79.7B trailing twelve months to June 2026; tirzepatide (Mounjaro and Zepbound) about 62%

Recent years are exact, taken from company filings; the earliest years are approximate. Forecast figures are Wall Street consensus, not company guidance. Read the full Eli Lilly moat analysis →